Guidelines on oral anticoagulation: Third edition

British Journal of Haematology

Volumn 101, Issue 2, 1998, Pages 374-387

  Baglin, T P ^a   Rose, P E ^a,a   Walker, I D ^a   Machin, S ^a   Barrowcliffe, T W ^a   Colvin, B T ^a   Greaves, M ^a   Ludlam, C A ^a   Mackie, I J ^a   Preston, F E ^a  

^a NONE

Author keywords

Anticoagulation; Guidelines; INR; Thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CARDIOMYOPATHY; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; LUNG EMBOLISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RHEUMATIC HEART DISEASE; STROKE; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS; VENA CAVA FILTER;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; DECISION MAKING, COMPUTER-ASSISTED; DRUG INTERACTIONS; HEMATOLOGY; HUMANS;

EID: 0001234754     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00715.x     Document Type: Review

References (129)

1. Ad Hoc Committee of the Working Group on Valvular Heart Disease European Society of Cardiology (1993) Guidelines for prevention of thromboembolic events in valvular heart disease. Journal of Heart Valve Disease, 2, 398-410.
2. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group (1994) Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet, 343, 499-503.
3. Antiplatelet Trialists Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vacular graft or arterial patency by antiplatelet therapy. British Medical Journal, 308, 159-168.
4. Arnold, A., Mick, M., Mazurek, R., Loop, F. & Trohman, R. (1992) Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. Journal of the American College of Cardioligists, 19, 851-855.
5. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data form five randomised controlled trials. Archives of Internal Medicine, 154, 1449-1457.
6. Baglin, T. (1994) Decentralised anticoagulant care. Clinical and Laboratory Haematology, 16, 327-329.
7. Baglin, T. & Luddington, R. (1997) Reliability of delayed INR determination: implications for decentralized anticoagulant care with off-site blood sampling. British Journal of Haematology, 96, 431-434.
8. Baker, R., Broward, J., Fang, H., Fisher, C., Groch, S., Heyman, A. & Karp, H. (1962) Anticoagulant therapy in cerebral infarction. Neurology, 12, 823-835.
9. Becker, R. & Ansell, J. (1996) Oral anticoagulants (antithrombotic agents) for cardiovascular disorders. Disorders of Thrombosis, pp. 75-89. Saunders, Philadelphia.
10. Bern, M., Lokich, J., Wallach, S., Bothe, A., Brenotti, P., Arkin, C., Greco, F., Huberman, M. & Moore, C. (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. Annals of Internal Medicine, 112, 423-428.
11. Bjerkelund, C. & Orning, O. (1969) The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. American Journal of Cardiology, 23, 208-216.
12. British Committee for Standards in Haematology (1990) Guidelines on oral anticoagulation: second edition. Journal of Clinical Pathology, 43, 177-183.
13. British Committee for Standards in Haematology (1993a) Guidelines on the prevention, investigation, and management of thrombosis associated with pregnancy. Journal of Clinical Pathology, 46, 489-496.
14. British Committee for Standards in Haematology (1993b) Guidelines on the use and monitoring of heparin 1992: second edition. Journal of Clinical Pathology, 46, 97-103.
15. British Committee for Standards in Haematology (1995) Guidelines for near patient testing. Clinical and Laboratory Haematology, 17, 301-310.
16. Cannegieter, S., Rosendaal, F. & Briet, E. (1994) Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation, 89, 635-641.
17. Cannegieter, S., Rosendaal, F., Wintzen, A., Van Der Meer, F., Vandenbroucke, J. & Briet, E. (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. New England Journal of Medicine, 333, 11-17.
18. Carson, J., Kelley, M., Duff, A., Weg, J., Fulkerson, W., Palevsky, H., Schwartz, J., Thompson, B., Popovich, J., Hobbins, T., Spera, M., Alavi, A. & Terrin, M. (1992) The clinical course of pulmonary embolism. New England Journal of Medicine, 326, 1240-1245.
19. Cavenagh, J. & Colvin, B. (1996) Guidelines for the management of thrombophilia. Postgraduate Medical Journal, 72, 87-94.
20. Chalmers, T., Matta, R., Smith, H. & Kunzler, A. (1977) Evidence favouring the use of anticoagulants in the hospital phase of acute myocardial infarction. New England Journal of Medicine, 297, 1091-1096.
21. Clagett, G. (1992) Antithrombotic therapy for lower extremity bypass. Journal of Vascular Surgery, 15, 867-875.
22. Cogo, A., Lensing, A., Koopman, M., Piovella, F., Siragusa, S., Wells, P., Villalta, S., Buller, H., Turpie, A. & Prandoni, P. (1998) Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. British Medical Journal, 316, 17-20.
23. Connolly, S., Laupacis, A., Gent, M., Roberts, R., Cairns, J., Joyner, C. and for the CAFA Study Coinvestigators (1991) Canadian Atrial Fibrillation Anticoagidation (CAFA) Study. Journal of the American College of Cardiologists, 18, 349-355.
24. Coon, W., Willis, P. & Symons, M. (1969) Assessment of anticoagulant treatment of venous thromboembolism. Annals of Surgery, 170, 559-568.
25. De Stefano, V., Finazzi, G. & Mannucci, P. (1996) Inherited thrombophilia. Blood, 87, 3531-3544.
26. del Zoppo, G. (1994) Antithrombotic therapy in cerebrovascular disease. Thrombosis and Haemorrhage, pp. 1225-1252. Blackwell Scientilic Publications, Boston.
27. Eckman, M., Levine, H. & Pauker, S. (1993) Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. New England Journal of Medicine, 329, 696-702.
28. Elliott, G. & Eklof, B. (1996) Vena caval filters. Disorders of Thrombosis, pp. 329-335. Saunders, Philadelphia.
29. European Atrial Fibrillation Trial Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet, ii, 1255-1262.
30. European Atrial Fibrillation Trial Study Group (1995) Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. New England Journal of Medicine, 333, 5-10.
31. Ezekowitz, M., Bridgers, S., James, K., Carliner, N., Colling, C., Gornick, C., Krause-Steinrauf, H., Kurtze, J., Narzarian, S., Radford, M., Rickles, F., Shabetai, R., Deykin, D., and for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New England Journal of Medicine, 327, 1406-1412.
32. Fennerty, A., Campbell, I. & Routledge, P. (1988) Anticoagulants in venous thromboembolism. British Medical Journal, 297, 1285-1288.
33. Fennerty, A., Dolben, J., Thomas, P., Backhouse, G., Bentley, D., Campbell, I. & Routledge, P. (1984) Flexible induction dose regimen for warfarin and prediction of maintenance dose. British Medical Journal, 288, 1268-1270.
34. Fihn, S., McDonell, M., Martin, D., Henikoff, J., Vermes, D., Kent, D. & White, R. (1993) Risk factors for complications of chronic anticoagulation: a multicenter study: warfarin optimised outpatient follow-up study group. Annals of Internal Medicine, 118, 511-520.
35. Fordyce, M., Baker, A. & Staddon, G. (1991) Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. British Medical Journal, 303, 219-220.
36. Francis, C. (1994) Prevention and treatment of venous thromboembolic disease. Thrombosis and Haemorrhage, pp. 1287-1311. Blackwell Scientific Publications, Boston.
37. Francis, C., Marder, V., Evarts, C. & Yaukoolbodi, S. (1983) Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. Journal of the American Medical Association, 249, 374-378.
38. Fuster, V., Gersh, B., Giulani, E., Tajik, A., Brandenburg, R. & Frye, R. (1981) The natural history of dilated cardiomyopathy. American Journal of Cardiology, 47, 525-531.
39. Gallus, A. (1988) Long term warfarin in artery disease. Blood Reviews, 2, 95-101.
40. Gallus, A., Jackaman, J., Tillett, J., Mills, W. & Wycherley, A. (1986) Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet, ii, 1293-1296.
41. Genton, E., Barnett, H., Fields, W., Gent, M. & Hoak, J. (1977) Cerebral ischaemia: the role of thrombosis and of antithrombotic therapy. Stroke, 8, 150-175.
42. Ginsberg, J. (1996) Drug therapy: management of venous thromboembolism. New England Journal of Medicine, 335, 1816-1828.
43. Ginsberg, J. & Barron, W. (1994) Pregnancy and prosthetic heart valves. Lancet, 344, 1170-1172.
44. Greaves, M. & Preston, F. (1991) Clinical and laboratory aspects of thrombophilia. Recent Advances in Blood Coagulation, pp. 119-140. Churchill Livingstone, Edinburgh.
45. Hall, J., Paul, R. & Wilson, K. (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. American Heart Journal, 68, 122-140.
46. Hart, R., Solomon, D. & Anderson, D. (1996) Oral anticoagulation for prevention of stroke and cerebral embolism. Oral Anticoagulants, pp. 150-166. Arnold, London.
47. Hirsh, J. (1990) Anticoagulant therapy in venous thromboembolism. Antithrombotic Therapy, pp. 685-692. Bailliere Tindall, London.
48. Hirsh, J. (1995) The optimal duration of anticoagulant therapy for venous thrombosis. New England Journal of Medicine, 332, 1710-1711.
49. Holmgren, K., Andersson, G., Fagrell, B., Johnsson, H., Ljungberg, B., Nilsson, E., Wilhelmsson, S. & Zetterquist, S. (1985) One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Medica Scandinavica, 218, 279-284.
50. Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D., McLoughlin, D. & Armstrong, P. (1979) Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. New England Journal of Medicine, 301, 855-858.
51. Hull, R., Hirsh, J., Jay, R., Carter, C., England, C., Gent, M., Turpie, A., McLoughlin, D., Dodd, P., Thomas, M., Raskob, G. & Ockelford, P. (1982) Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine, 307, 1676-1681.
52. Hull, R., Raskob, G., Rosenbloom, D., Panju, A., Brill-Edwards, P., Ginsberg, J., Hirsh, J., Martin, G. & Green, D. (1990) Heparin for 5 days as compared to 10 days in the initial treatment of proximal vein thrombosis. New England Journal of Medicine, 322, 1260-1264.
53. Hunt, B. (1995) Development of a MUMPS-based anticoagulant management system. British Journal of Biomedical Science, 50, 117-124.
54. Hylek, E. & Singer, D. (1994) Risk factors for intracranial haemorrahge in outpatients taking warfarin. Annals of Internal Medicine, 120, 897-902.
55. Hylek, E., Skates, S., Sheehan, M. & Singer, D. (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. New England Journal of Medicine, 335, 540-546.
56. Iturbe-Alessio, I., del Carmen Fonseca, M., Mutchinik, O., Santos, M., Zajarias, A. & Salazaar, E. (1986) Risks of anticoagulant therapy in pregnant women with artificial heart valves. New England Journal of Medicine, 315, 1390-1393.
57. Kakkar, V., Flanc, C., Howe, C. & Clarke, M. (1969) Natural history of postoperative deep vein thrombosis. Lancet, ii, 230-233.
58. Kathol, R., Nolan, S. & McGuire, L. (1976) Living with prosthetic valves: subsequent non-cardiac operations and the risk of thromboembolism or hemorrhage. American Heart Journal, 92, 162-167.
59. Kearon, C. & Hirsh, J. (1997) Management of anticoagulation before and after elective surgery. New England Journal of Medicine, 336, 1506-1511.
60. Khamashta, M., Cuadrado, M., Mujic, F., Taub, N., Hunt, B. & Hughes, G. (1995) The management of thrombosis in the antiphospholipid syndrome. New England Journal of Medicine, 332, 993-997.
61. Kretschmer, G., Wenzl, E., Schemper, M., Polterauer, P., Ehringer, H., Marcosi, L. & Minar, E. (1988) Influence of postoperative anticoagulant treatment on patient survival after femeropopliteal vein bypass surgery. Lancet, i, 797-799.
62. Lagerstedt, C., Olsson, C., Fagher, B., Oqvist, B. & Albrechtsson, V. (1985) Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet, ii, 515-518.
63. Landefeld, C., Rosenblatt, M. & Goldman, L. (1989) Bleeding in outpatients teated with warfarin: relation to the prothrombin time and important remedial lesions. American Journal of Medicine, 87, 153-159.
64. Lane, D., Mannucci, P., Bauer, K., Bertina, R., Bochkov, N., Boulyjenkov, V., Chandy, M., Dahlback, B., Ginter, E., Miletich, J., Rosendaal, F. & Seligsohn, U. (1996) Inherited thrombophilia. Thrombosis and Haemostasis, 76, 824-834.
65. Laupacis, A. (1996) Atrial fibrillation and oral anticoagulants. Oral Anticoagulants, pp. 123-129. Arnold, London.
66. Laupacis, A. & Albers, G. (1995) Atrial fibrillation. Disorders of Thrombosis, pp. 106-115. Saunders, Philadelphia.
67. Levine, H., Pauker, S. & Eckman, M. (1992) Antithrombotic therapy in valvular heart disease. Chest, 102, 434S-444S.
68. Levine, M., Hirsh, J., Gent, M., Arnold, A., Warr, D., Falanga, A., Samosh, M., Bramwell, V., Pritchard, K., Stewart, D. & Goodwin, P. (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, 343, 886-889.
69. Levine, M., Hirsh, J., Gent, M., Turpie, A., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J., Powers, P. & Piovella, F. (1995) Optimal duration of oral anticoagulant therapy: a randomised trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thrombosis and Haemostasis, 74, 606-611.
70. Lohr, J., Kerr, T., Lutter, K., Cranley, R., Spirtoff, K. & Cranky, J. (1991) Lower extremity calf thrombosis: to treat or not to treat? Journal of Vascular Surgery, 14, 618-623.
71. Lowe, G. (1996) Acute stroke. Disorders of Thrombosis, pp. 116-125. Saunders, Philadelphia.
72. Machin, S., Mackie, I., Chitolie, A. & Lawrie, A. (1996) Near patient testing (NPT) in haemostasia: a synoptic review. Clinical and Laboratory Haematology, 18, 69-74.
73. Makris, M., Greaves, M., Philips, W., Kitchen, S., Rosendaal, F. & Preston, F. (1996) Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thrombosis and Haemostasis, 77, 477-480.
74. McLinley, L. & Wrenn, K. (1993) Are baseline prothrombin time/ partial thromboplastin time values necessary before instituting anticoagulation? Annals of Emergency Medicine, 22, 697-702.
75. Meade, T., Wilkes, H., Stirling, Y., Brennan, P., Kelleher, C. & Browne, W. (1988) Randomised controlled trial of low dose warfarin in the primary prevention of ischemic heart disease. European Heart Journal, 9, 836-843.
76. Mohiuddin, S., Hilleman, D., Destache, C., Stoysich, A., Gannon, J. & Sketch, M. (1992) Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. American Heart Journal, 123, 729-732.
77. Moriarty, H., Lam-Po-Tang, P. & Anastas, N. (1988) Comparison of thromboplastins using the ISI and INR system. Pathology, 10, 67-71.
78. Nunez, L., Aguado, G., Larrea, J., Celemin, D. & Oliver, J. (1984) Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Annals of Thoracic Surgery, 57, 84-87.
79. O'Sullivan, E. (1972) Duration of anticoagulant therapy in venous thromboembolism. Medical Journal of Australia, ii, 1104-1107.
80. Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., Devoto, G., Berettini, M., Musolesi, S., on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet, 348, 423-428.
81. Pellegrini, V., Langhaus, M., Totterman, S., Marder, V. & Francis, C. (1993) Embolic complications of calf thrombosis following total hip arthroplasty. Journal of Arthroplasty, 8, 449-457.
82. Peters, R., Van den Besselaar, A. & Olthius, F. (1991) Determination of mean normal prothrombin time for the assessment of INR. Thrombosis and Haemostasis, 66, 442-445.
83. Peterson, P., Boysen, G., Godtfredsen, J., Andersen, E. & Andersen, B. (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet, i, 175-179.
84. Petili, O., Strom, B. & Melmon, K. (1986) Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. American Journal of Medicine, 81, 255-259.
85. Pfisterer, M., Burkart, F., Jockers, G., Meyer, B., Regenass, S., Burckhardt, D., Schmitt, H., Muller-Brand, J., Skarvan, K. & Stulz, P. (1989) Trial of low-dose aspirin plus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet, ii, 1-7.
86. Philips, W., Makris, M. & Preston, F. (1995) Audit of frequency and clinical response to excessive oral anticoagulation. British Journal of Haematology, 84, (Suppl. 1), 57 (A129).
87. Poller, L., McKernan, A., Thomson, J., Elstein, M., Hirsch, P. & Jones, J. (1987) Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. British Medical Journal, 295, 1309-1312.
88. Poller, L., Thomson, J. & Taberner, D. (1989) Effect of automation on the prothrombin time test in NEQAS surveys. Journal of Clinical Pathology, 42, 97-100.
89. Poller, L., Triplett, D., Hirsh, J., Carroll, J. & Clark, K. (1995) The value of plasma calibrants in correcting coagulometer effects on international normalised ratios. American Journal of Chemical Pathology, 103, 358-365.
90. Preston, F. (1995) Quality control and oral anticoagulation. Thrombosis and Haemostasis, 74, 515-520.
91. Ramstrom, G., Sindet-Pederson, S., Hall, G., Blomback, M. & Alander, U. (1993) Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. Journal of Oral and Maxillofacial Surgery, 51, 1211-1216.
92. Raskob, G. (1996) Calf-vein thrombosis. Disorders of Thrombosis, pp. 398-405. Saunders, Philadelphia.
93. Report of the Sixty-Plus Reinfarction Study Research Group (1980) A double blind trial to assess long term anticoagulant therapy in elderly patients after myocardial infarction. Lancet, ii, 989-993.
94. Research Committee of the British Thoracic Society (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet, 340, 873-876.
95. Rose, P. (1996) Audit of anticoagulant therapy. Journal of Clinical Pathology, 49, 5-9.
96. Rosiello, R., Chan, C., Tencza, F. & Matthay, R. (1987) Timing of oral anticoagulation therapy in the treatment of angiographically proven acute pulmonary embolism. Archives of Internal Medicine, 147, 1469-1473.
97. Ryan, P., Gilbert, M. & Rose, P. (1989) Computer control of anticoagulant dose for therapeutic management. British Medical Journal, 299, 1207-1209.
98. Sandler, D. & Martin, J. (1989) Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? Journal of the Royal Society of Medicine, 82, 203-205.
99. Sbarouni, E. & Oakley, C. (1994) Outcome of pregnancy in women with va:ve prostheses. British Heart Journal, 71, 196-201.
100. Schecter, A., Fuster, V. & Chesebro, J. (1996) Anticoagulants in cardiomyopathy. Oral Anticoagulants, pp. 258-263. Arnold, London.
101. Schulman, S., Granqvist, S., Holmstrom, M., Carlsson, A., Lindmarker, P., Nicol, P., Eklund, S.-G., Nordlander, S., Larfars, G., Leijd, B., Linder, O., Loogna, E., and the Duration of Anticoagulation Trial Study Group (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. New England Journal of Medicine, 336, 393-398.
102. Schulman, S., Rhedin, A., Lindmarker, P., Carlsson, A., Larfars, G., Nicol, P., Loogna, E., Svensson, S., Ljungberg, B., Walter, H., Viering, S., Nordlander, S., Leijd, B., Jonsson, K.-A., Hjorth, M., Linder, O., Boberg, J., and the Duration of Anticoagulation Trial Study Group (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. New England Journal of Medicine, 332, 1661-1665.
103. Sherman, D., Dyken, M., Fisher, M., Gent, M., Harrison, M. & Hart, R. (1992) Antithrombotic therapy for cerebrovascular disorders. Chest, 102, (Suppl.), 529S-537S.
104. Shetty, H., Backhouse, G., Bentley, D. & Routledge, P. (1992) Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thrombosis and Haemostasis, 67, 13-15.
105. Smith, P., Arnesen, H. & Holme, I. (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. New England Journal of Medicine, 323, 147-152.
106. Stein, P., Alpert, J., Copeland, C., Dalen, J., Goldman, S. & Turpie, A. (1992) Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest, 102, (Suppl.), 445S-455S.
107. Stein, P., Alpert, J., Copeland, J., Dalen, J. & Turpie, A. (1995) Antithrombotic therapy in patients with mechanical and bioprosthetic heart valves. Chest, 108, 371S-379S.
108. Stroke Prevention in Atrial Fibrillation Investigators (1991) Stroke prevention in atrial fibrillation study: final results. Circulation, 84, 527-539.
109. Stroke Prevention in Atrial fibrillation Investigators (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet, 343, 687-691.
110. Stroke Prevention in Atrial Fibrillation Investigators (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet, 348, 633-638.
111. Taberner, D., Poller, L., Burslem, R. & Jones, J. (1978) Oral anticoagulants controlled by the British Comparative Thromboplastin versus low-dose heparin prophylaxis of deep vein thrombosis. British Medical Journal, ii, 272-274.
112. Taberner, D., Poller, L. & Thompson, J. (1989) Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR). Journal of Clinical Pathology, 42, 1-3.
113. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New England Journal of Medicine, 323, 1505-1511.
114. The EPSIM Research Group (1982) A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. New England Journal of Medicine, 307, 701-708.
115. Thorton, M., Gruentzig, A., Hollman, J., King, S. & Douglas, J. (1984) Coumadin and aspirin in the prevention of recurrence after transluminal coronary angioplasty: a randomised study. Circulation, 69, 721-727.
116. Tillgren, C. (1965) Obliterative arterial disease of the lower limbs. IV. Evaluation of long-term anticoagulant therapy. Acta Medica Scandinavica, 178, 203-219.
117. Tinker, J. & Tarhan, S. (1978) Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Journal of the American Medical Association, 239, 738-739.
118. Turpie, A. (1996) Valvular heart disease and heart valve prostheses. Oral Anticoagulants, pp. 143-149. Arnold, London.
119. Turpie, A., Gunstensen, J., Hirsh, J., Nelson, H. & Gent, M. (1988) Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet, i, 1242-1245.
120. US Department of Health and Human Services, Public Health Service and Agency Care Policy and Research (1992) Acute pain management: operative or medical procedures and trauma. Agency for Health Care Policy and Research Publications, Report AHCPR Pub 92-0058.
121. Vaitkus, P. & Barnathan, E. (1993) Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. Journal of the American College of Cardiologists, 22, 1004-1009.
122. van der Meer, F., Rosendaal, F., Vandenbroucke, J. & Briet, E. (1993) Bleeding complications in oral anticoagulant therapy. Archives of Internal Medicine, 153, 1557-1562.
123. Van der Meer, J., Hillege, H., Ascoop, C., Pfisterer, M., Van Gilst, W. & Lie, K. (1993) Prevention of one-year vein-graft occlusion after aortocoronary bypass surgery: a comparison of low dose aspirin, low dose aspirin plus dipyridamole, and oral anticoagulants. Lancet, 342, 257-264.
124. Weinberg, D. & Mancini, J. (1989) Anticoagulation for cardioversion of atrial fibrillation. American Journal of Cardiology, 63, 745-746.
125. Weinmann, E. & Salzman, E. (1994) Deep-vein thrombosis. New England Journal of Medicine, 331, 1630-1641.
126. White, R., McKittrick, T., Hutchinson, R. & Twitchell, J. (1995) Temporary discontinuation of warfarin therapy: changes in the international normalised ratio. Annals of Internal Medicine, 122, 40-42.
127. WHO Expert Committee on Biological Standardisation (1983) Report 33. WHO Technical Report Series, 687, 81-105.
128. Wolf, P., Daeber, T., Emerson, T. & Krannel, W. (1978) Epidemiological assessment of chronic atrial fibrillation and the risk of stroke: the Framingham Study. Neurology, 28, 973-977.
129. Wong, V., Cheng, C. & Chan, K. (1993) Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. American Journal of Medical Genetics, 45, 17-21.